Activation of the STING pathway potentiates the antitumor efficacy of doxorubicin in soft-tissue sarcoma
Activation of STING pathway by ADU-S100 enhances the antitumor efficacy of doxorubicin in STS. Combining doxorubicin with STING agonists may be a promising therapeutic strategy worth exploring in future clinical trials.
Authors
- Gi Yeon Lee
- Wonyoung Choi (ORCID: https://orcid.org/0000-0002-5317-2055)
- Sun-Young Kong
Institutions
- National Cancer Center (US)
- National Cancer Center (KR)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-12
- DOI
- https://doi.org/10.3389/fonc.2025.1634503
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea